DevCo 為 Medix Biochemica 完成 6.16 億歐元長(zhǎng)期單項(xiàng)資產(chǎn)投資安排
● DevCo 為其對(duì) Medix Biochemica 的長(zhǎng)期投資完成了一次戰(zhàn)略性資本募集。
DevCo has completed a strategic capital raise for its long-term investment in Medix Biochemica.
● 基于本次募資，DevCo 的 Medix Biochemica 專項(xiàng)單項(xiàng)資產(chǎn)投資平臺(tái)獲得了總計(jì) 6.16 億歐元長(zhǎng)期投資承諾。
Following the capital raise, DevCo’s single-asset investment vehicle for Medix Biochemica has total longterm commitments of 616 MEUR.
● 此次募資由 Council Ring Capital 領(lǐng)投，Council Ring Capital 是總部位于芝加哥的單一家族事務(wù)公司，主要投資于醫(yī)療保健、技術(shù)和消費(fèi)領(lǐng)域的成長(zhǎng)型企業(yè)。此次募資的主要投資者還包括 Security Trading (Antti Herlin家族投資公司)、基石投資者 Coller Capital，以及其他投資者。
The capital raise was led by Council Ring Capital, a Chicago-based, single-family office investing in growing businesses across the healthcare, technology, and consumer sectors. Other major investors in the capital raise included, among others, Security Trading (the investment company of Antti Herlin’s family) and cornerstone investor Coller Capital.
● Medix Biochemica 是體外診斷行業(yè)全球領(lǐng)先的關(guān)鍵生物原料獨(dú)立供應(yīng)商，在 DevCo 成為控股股東之后的六年中發(fā)展迅速。
Medix Biochemica, a leading independent provider of critical biological raw material products for the in vitro diagnostics industry, has developed rapidly during the first six years of DevCo’s ownership.
● 本次募集的資金將使 Medix Biochemica 得以按照公司既定的增長(zhǎng)戰(zhàn)略、在積極推進(jìn)有機(jī)增長(zhǎng)的同時(shí)、進(jìn)一步推動(dòng)非運(yùn)營(yíng)性增長(zhǎng)計(jì)劃、諸如并購(gòu)。
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives alongside active organic development in accordance with the company’s growth strategy.
2024 年 9 月 3 日，芬蘭赫爾辛基 —— DevCo 合伙有限公司 ("DevCo") 很高興地宣布，其為 Medix Biochemica 專項(xiàng)長(zhǎng)期單項(xiàng)資產(chǎn)投資平臺(tái)組織的募資已獲得總計(jì) 6.16 億歐元的承諾。作為本次交易的一部分，約 3 億歐元的新投資已經(jīng)被注入到該投資平臺(tái)中，這為 DevCo 提供了大量額外資本，以繼續(xù)支持 Medix Biochemica 的長(zhǎng)期增長(zhǎng)戰(zhàn)略。新資本由一批強(qiáng)大的投資者提供，其中包括領(lǐng)投投資者 Council Ring Capital、Antti Herlin (在此次募資之前，他一直是該投資平臺(tái)的主要投資者)、以及基石投資者 Coller Capital、養(yǎng)老基金 Keva、VER 和 Elo?，F(xiàn)有的長(zhǎng)期投資者，如 Minerva 基金會(huì)、C. Ehrnrooth 家族、Rettig 和 Ilmarinen 等，在此次募資后將繼續(xù)作為該投資平臺(tái)的關(guān)鍵投資者。
3 September 2024, Helsinki, Finland – DevCo Partners Ltd (“DevCo”) is pleased to announce a capital raise resulting in 616 MEUR of total commitments for its long-term single asset investment vehicle for Medix Biochemica. The transaction, as part of which ca. 300 MEUR of new investments were raised to the investment vehicle, provides DevCo with significant additional capital for continued support of the long-term growth strategy of Medix Biochemica. The new capital was provided by a strong group of investors including, among others, lead investor Council Ring Capital and Antti Herlin (who has been a major anchor investor in the vehicle before the capital raise) as well as cornerstone investors Coller Capital and pension funds Keva, VER and Elo. Existing longstanding investors, such as the Minerva Foundation, the C. Ehrnrooth family, Rettig and Ilmarinen will also continue as key investors in the vehicle following the capital raise.
Medix Biochemica 總部位于芬蘭，是體外診斷行業(yè) (IVD) 全球領(lǐng)先的關(guān)鍵生物原料獨(dú)立供應(yīng)商。公司開發(fā)、生產(chǎn)并向全球 IVD 試劑制造商供應(yīng)高品質(zhì)的抗體、抗原及其他關(guān)鍵 IVD 原料，從而使全球數(shù)十億患者得以獲得精準(zhǔn)的 IVD 檢測(cè)結(jié)果。公司的專長(zhǎng)覆蓋免疫檢測(cè)、臨床生化、分子診斷等各個(gè)細(xì)分領(lǐng)域。Medix Biochemica 在全球擁有超過(guò) 250 名專業(yè)人員，并通過(guò)其在中國(guó)、歐洲、和北美的當(dāng)?shù)貓F(tuán)隊(duì)為其全球客戶提供服務(wù)。
Finland-headquartered Medix Biochemica is a leading independent supplier of critical biological raw material products to the in vitro diagnostics (IVD) industry worldwide. The company develops, produces, and supplies high-quality antibodies, antigens, and other critical IVD raw material products to IVD test manufacturers around the world, enabling the delivery of accurate IVD tests to billions of patients worldwide. The company’s expertise covers various market segments including immunoassay, clinical chemistry and molecular diagnostics. Medix Biochemica employs over 250 professionals worldwide and it serves its global customers through local teams in North America, Europe, and China.
DevCo 與前控股股東 Minerva 基金會(huì)合作，于 2018 年 2 月獲得了Medix Biochemica 的多數(shù)股權(quán)，以致力于加速該公司的成長(zhǎng)和發(fā)展。在 DevCo 成為控股股東的這頭六年中，通過(guò)重大有機(jī)增長(zhǎng)計(jì)劃的實(shí)施、和在美國(guó)及歐洲進(jìn)行的七次戰(zhàn)略收購(gòu)，Medix Biochemica極大地強(qiáng)化了其作為體外診斷行業(yè)首選原料合作伙伴的戰(zhàn)略地位。基于這些并購(gòu)和高于市場(chǎng)平均水平的有機(jī)增長(zhǎng)，公司的銷售額從 2017 年的兩千萬(wàn)歐元增長(zhǎng)到 2023 年的七千余萬(wàn)歐元。
DevCo partnered with the previous main owner Minerva Foundation and acquired a majority stake in Medix Biochemica in February 2018 with an aim to accelerate the growth and development of the company. During DevCo’s first six years of ownership, Medix Biochemica has significantly strengthened its strategic position as the first choice raw material partner for the in vitro diagnostics industry through execution of significant organic development initiatives and seven strategic acquisitions in the US and Europe. As a result of the acquisitions and above-market organic growth, the company’s sales have grown from 20 MEUR in 2017 to 70 MEUR in 2023.
“DevCo 的使命是在具有長(zhǎng)期吸引力的細(xì)分市場(chǎng)中持續(xù)地打造具有世界領(lǐng)先地位的公司。在我們成為 Medix Biochemica 控股股東的這頭六年里，該公司已轉(zhuǎn)變?yōu)轭I(lǐng)先的關(guān)鍵 IVD 原料獨(dú)立供應(yīng)商，擁有真正全球化的業(yè)務(wù)、全面的高品質(zhì)產(chǎn)品線、以及龐大的全球客戶群。此次募資是我們對(duì) Medix Biochemica 長(zhǎng)期投資的一個(gè)重要里程碑，為公司加速增長(zhǎng)戰(zhàn)略的下一階段提供了充足的資源。我們感謝現(xiàn)有投資者在這項(xiàng)長(zhǎng)期投資中給予的持續(xù)支持，并非常高興地歡迎以 Council Ring Capital 為首的新投資者的加入。此外，我們還要感謝 Medix Biochemica 全體員工為公司雄心勃勃的增長(zhǎng)戰(zhàn)略所做的出色工作和堅(jiān)定承諾。” Medix Biochemica 董事會(huì)副主席兼 DevCo Partners 合伙人 Teemu Alahuhta 表示。
“DevCo’s mission is to sustainably develop world-leading companies in fundamentally attractive niche markets. During the first six years of our ownership of Medix Biochemica, the company has transformed into a leading independent provider of critical IVD raw material products with truly global operations, broad highquality offering and vast global customer base. This capital raise represents a significant milestone in our long-term investment in Medix Biochemica by providing adequate resources for the next phase of the company’s accelerated growth strategy. We are grateful for the continued support of our existing investors in this long-term investment and very pleased to welcome the new investors, led by Council Ring Capital, to the investor base. In addition, we would like to thank the whole personnel of Medix Biochemica for the great work and strong commitment to the company’s ambitious growth strategy”, says Teemu Alahuhta, Vice Chair of the Board of Directors of Medix Biochemica and partner of DevCo Partners.
“Medix Biochemica 與 DevCo 的合作在過(guò)去六年中對(duì)公司的轉(zhuǎn)型增長(zhǎng)起到了重要作用。DevCo 團(tuán)隊(duì)履行了他們的所有承諾，為 Medix Biochemica 加速增長(zhǎng)戰(zhàn)略的執(zhí)行提供了長(zhǎng)期資本和實(shí)實(shí)在在的資源。對(duì)于 Medix Biochemica 這樣追求全球市場(chǎng)領(lǐng)導(dǎo)地位的高質(zhì)量中型公司來(lái)說(shuō)，此次資本募集不僅為其持續(xù)增長(zhǎng)投資提供了支持，還凸顯了 DevCo 作為一家專注、負(fù)責(zé)且具有長(zhǎng)期導(dǎo)向的增長(zhǎng)伙伴所具有的獨(dú)特定位。” Medix Biochemica 董事會(huì)主席 Ann-Christine Sundell 表示。
“Medix Biochemica’s partnership with DevCo has been instrumental in enabling the transformational growth of the company in the past six years. The DevCo team has done everything they promised and provided both long-term capital and committed hands-on resources for the execution of Medix Biochemica’s accelerated growth strategy. This capital raise not only enables continued growth investments for Medix Biochemica but also underlines DevCo’s unique positioning as a dedicated, responsible and long-term oriented growth partner for high-quality medium-sized companies aiming for global market leadership”, says Ann-Christine Sundell, Chair of the Board of Directors of Medix Biochemica.
“我們很高興能與 DevCo 的世界級(jí)合作伙伴及投資集團(tuán)一起，為 Medix Biochemica 這樣卓越的企業(yè)的下一階段增長(zhǎng)提供支持。” Council Ring Capital 首席投資官 Chuck Murphy 表示。“通過(guò)其愿景和努力，DevCo 已將 Medix Biochemica 打造成為全球 IVD 制造商首選的原料供應(yīng)商。我們期待提供在醫(yī)療保健行業(yè)的專業(yè)知識(shí)、人脈和資本，以支持 DevCo 和 Medix Biochemica。” Council Ring Capital 負(fù)責(zé)人兼醫(yī)療保健部門主管 Marc Gruenhut 補(bǔ)充道。
“We are delighted to help support the next phase of growth for Medix Biochemica, which is an exceptional business, alongside world-class partners at DevCo and its investor group,” says Chuck Murphy, Chief Investment Officer of Council Ring Capital. “Through its vision and efforts, DevCo has transformed Medix Biochemica into the raw material supplier of choice to the world’s IVD manufacturers. We look forward to contributing complementary healthcare expertise, network connectivity, and capital in support of DevCo and Medix Biochemica,” added Marc Gruenhut, Principal & Healthcare Sector Lead at Council Ring Capital.
“Medix Biochemica 恰好代表了我們樂(lè)于投資的那種公司，它是一個(gè)在具有韌性且不斷增長(zhǎng)的市場(chǎng)中的高質(zhì)量參與者。此次交易凸顯了 Coller Capital 在北歐二級(jí)市場(chǎng)和醫(yī)療保健領(lǐng)域的實(shí)力，我們很高興在此次交易中與 DevCo 合作。” Coller Capital 負(fù)責(zé)人 Martin Fleischer 說(shuō)到。
“Medix Biochemica represents exactly the kind of company we like to invest in, being a high-quality player in a resilient and growing market. This transaction underscores Coller Capital’s strength in the Nordic secondaries market and the healthcare sector and we are excited to partner with DevCo in this transaction”, says Martin Fleischer, principal at Coller Capital.
欲了解更多信息，請(qǐng)?jiān)L問(wèn) www.devco.fi。
聯(lián)系信息：
DevCo Partners 合伙人 Teemu Alahuhta
電話：+358 10 235 4820
電子郵箱：teemu.alahuhta@devco.fi
● DevCo 簡(jiǎn)介
DevCo 是一家具有長(zhǎng)期導(dǎo)向的積極型股東和發(fā)展伙伴，致力于在選定的細(xì)分市場(chǎng)中打造世界領(lǐng)先的公司。DevCo 為其旗下公司提供實(shí)際操作資源、戰(zhàn)略支持和財(cái)務(wù)資源，以支持其業(yè)績(jī)實(shí)現(xiàn)重大提升。DevCo 目前是三家全球細(xì)分市場(chǎng)領(lǐng)導(dǎo)者 —— Vexve、Medix Biochemica 和 Bluefors 的重要股東。
● Council Ring Capital 簡(jiǎn)介
Council Ring Capital 是一家總部位于芝加哥的單一家族事務(wù)公司，投資于醫(yī)療保健、技術(shù)和消費(fèi)領(lǐng)域的成長(zhǎng)型企業(yè)。該公司尋求進(jìn)行長(zhǎng)期股權(quán)投資，在此過(guò)程中，其團(tuán)隊(duì)利用其雄厚的資本、人脈和專長(zhǎng)，與被投資方共同推動(dòng)以取得成功。
聯(lián)系我們
Medix Biochemica China
上海墨迪斯醫(yī)療技術(shù)有限公司
上海市閔行區(qū)浦江鎮(zhèn)綠洲環(huán)路10號(hào)6幢11層
電話：021-68119180,68119105,68119181
郵箱：medixchina@medixbiochemica.com
網(wǎng)站：onb2b.cn
